467442-06-4

Upstream product

• 7677-24-9 trimethylsilyl cyanide 
• 74733-30-5 methyl 4-Bromomethyl-3-chlorobenzoate 
• 10442-39-4 tetra-n-butylammonium cyanide 
• 56525-63-4 methyl 3-chloro-4-methyl-benzoate 

Downstream Products

• 1134776-89-8 (±)-methyl 4-(1-aminoethyl)-3-chlorobenzoate 
• 484648-98-8 methyl 4-{2-[((2S)-2-{[(benzyloxy)carbonyl]amino}-4,4-difluorobutanoyl)amino]-ethyl}-3-chlorobenzoate 
• 484648-97-7 4-(2-{[(2S)-2-amino-4,4-difluorobutanoyl]amino}ethyl)-3-chlorobenzoate 
• 734528-30-4 4-(2-amino-ethyl)-3-chloro-benzoic acid methyl ester 

Relevant academic research and scientific papers

P300/CBP HAT INHIBITORS

Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with histone acetyltransferase (HAT).

3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

Phenethyl amides as novel noncovalent inhibitors of hepatitis C virus NS3/4A protease: Discovery, initial SAR, and molecular modeling

The discovery of novel, reversible and competitive tripeptide inhibitors of the Hepatitis C virus NS3/4A serine protease is described. These inhibitors are characterized by the presence of a C-terminal phenethyl amide group, which extends into the prime side of the enzyme. Initial SAR together with molecular modeling and data from site-directed mutagenesis suggest an interaction of the phenethyl amide group with Lys-136.